CORONA Remedies Limited (NSE:CORONA)

Market Cap	107.07B
Revenue (ttm)	14.03B +20.1%
Net Income	1.85B +31.6%
EPS	30.27 +31.7%
Shares Out	61.16M
PE Ratio	57.83
Forward PE	42.83
Dividend	10.00 (0.58%)
Ex-Dividend Date	n/a

Volume	8,126
Open	1,731.70
Previous Close	1,731.70
Day's Range	1,728.60 - 1,757.00
52-Week Range	1,336.60 - 1,949.40
Beta	n/a
Analysts	Strong Buy
Price Target	1,860.67 (+6.29%)
Earnings Date	Aug 14, 2026

About CORONA Remedies

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 4,500
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CORONA

Financial Performance

In fiscal year 2026, CORONA Remedies's revenue was 14.03 billion, an increase of 17.28% compared to the previous year's 11.96 billion. Earnings were 1.85 billion, an increase of 23.88%.

Analyst Summary

According to 3 analysts, the average rating for CORONA stock is "Strong Buy." The 12-month stock price target is ₹1,861, which is an increase of 6.29% from the latest price.

Price Target

₹1,861

(6.29% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 17, 2026

Data Sources Report a data error